133 related articles for article (PubMed ID: 10090791)
1. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Ohmachi Y; Kikkawa H; Ikezawa K; Naito K
J Med Chem; 1999 Mar; 42(6):1088-99. PubMed ID: 10090791
[TBL] [Abstract][Full Text] [Related]
2. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.
Van der Mey M; Bommelé KM; Boss H; Hatzelmann A; Van Slingerland M; Sterk GJ; Timmerman H
J Med Chem; 2003 May; 46(10):2008-16. PubMed ID: 12723963
[TBL] [Abstract][Full Text] [Related]
4. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
5. Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
Iwasaki T; Kondo K; Kuroda T; Moritani Y; Yamagata S; Sugiura M; Kikkawa H; Kaminuma O; Ikezawa K
J Med Chem; 1996 Jul; 39(14):2696-704. PubMed ID: 8709099
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
[TBL] [Abstract][Full Text] [Related]
7. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.
Aoki M; Fukunaga M; Sugimoto T; Hirano Y; Kobayashi M; Honda K; Yamada T
J Pharmacol Exp Ther; 2001 Sep; 298(3):1142-9. PubMed ID: 11504812
[TBL] [Abstract][Full Text] [Related]
8. Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).
Macdonald D; Perrier H; Liu S; Laliberté F; Rasori R; Robichaud A; Masson P; Huang Z
J Med Chem; 2000 Oct; 43(21):3820-3. PubMed ID: 11052785
[No Abstract] [Full Text] [Related]
9. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
[TBL] [Abstract][Full Text] [Related]
10. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
Bioorg Med Chem Lett; 2001 Jan; 11(1):33-7. PubMed ID: 11140727
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
[TBL] [Abstract][Full Text] [Related]
12. CDP840: a novel inhibitor of PDE-4.
Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
[TBL] [Abstract][Full Text] [Related]
13. Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
Kim E; Chun HO; Jung SH; Kim JH; Lee JM; Suh BC; Xiang MX; Rhee CK
Bioorg Med Chem Lett; 2003 Jul; 13(14):2355-8. PubMed ID: 12824033
[TBL] [Abstract][Full Text] [Related]
14. Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.
Côté B; Frenette R; Prescott S; Blouin M; Brideau C; Ducharme Y; Friesen RW; Laliberté F; Masson P; Styhler A; Girard Y
Bioorg Med Chem Lett; 2003 Feb; 13(4):741-4. PubMed ID: 12639571
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity.
Ferrari F; Mennuni L; Caselli G; Zanelli T; Makovec F
Eur J Pharmacol; 2004 Nov; 504(3):223-33. PubMed ID: 15541426
[TBL] [Abstract][Full Text] [Related]
16. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
17. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Hughes B; Howat D; Lisle H; Holbrook M; James T; Gozzard N; Blease K; Hughes P; Kingaby R; Warrellow G; Alexander R; Head J; Boyd E; Eaton M; Perry M; Wales M; Smith B; Owens R; Catterall C; Lumb S; Russell A; Allen R; Merriman M; Bloxham D; Higgs G
Br J Pharmacol; 1996 Jul; 118(5):1183-91. PubMed ID: 8818342
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
[TBL] [Abstract][Full Text] [Related]
19. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
Dal Piaz V; Giovannoni MP; Castellana C; Palacios JM; Beleta J; Doménech T; Segarra V
J Med Chem; 1997 May; 40(10):1417-21. PubMed ID: 9154964
[TBL] [Abstract][Full Text] [Related]
20. Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs.
Kapui Z; Schaeffer P; Mikus EG; Boronkay E; Gyürky J; Herbert JM; Pascal M
Arzneimittelforschung; 1999 Aug; 49(8):685-93. PubMed ID: 10483515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
